Case Study: Castrate-Resistant Prostate Cancer

Share this content:
Neal D. Shore
Neal D. Shore

Case Presentation

A 62-year-old male underwent a radical prostatectomy for a Gleason 7 (4 of 12 cores positive), prostate cancer, with a preoperative prostate specific antigen (PSA) level of 10.0ng/mL and baseline unremarkable bone/CT scans. 

The patient's postoperative PSA was undetectable for the first 6 months and then was noted to be 0.5ng/mL. The patient opted to postpone adjuvant radiation therapy for fear of impacting his normal voiding and sexual function. Instead, he chose serial PSA surveillance, a rigorous exercise program, and a macrobiotic diet with several over-the-counter supplements.

During his surveillance period of approximately 30 months, with PSA monitoring every 4 months, his PSA level increased, and eventually reached a level of 10ng/mL. Repeat bone scan and CT scans at that time were unremarkable for metastases.

Nonetheless, a decision was made to initiate androgen deprivation therapy, and he received a 4-month luteinizing hormone releasing hormone (LHRH) agonist. A baseline dual-energy X-ray absorptiometry (DEXA) scan was obtained to evaluate bone-mineral density, which was within normal limits. The patient was started on vitamin D and calcium supplements.

Over the course of the next 7 months, the patient's PSA nadired to 0.2ng/mL and remained stable for the next several years.

At age 69, the patient's PSA level began to rise again, from 0.22 to 0.52, and then subsequently to 0.9; his PSA remained stable at 2.3ng/mL for several months. Repeat bone scans and CAT scans were negative. The patient received an anti-androgen bicalutamide (50mg) and, for a period of a few months, his PSA level decreased to 1.1. However, after 4 months, his PSA level returned to 2.9.

Questions for Discussion

  1. What is the role for anti-androgen withdrawal?
  2. What is the role for switching to another anti-androgen?
  3. What is the role for ketoconazole, with or without hydrocortisone?
  4. What is the role for estrogen therapy?
Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs